Anxiety or depressive symptoms are known to be predictors of impaired health-related quality of life (HRQoL). However, little research has focused on the impact of Type D personality as chronic psychological distress on HRQoL in atrial fibrillation (AF) patients. Increased high-sensitivity C-reactive protein (hsCRP) is likely to be associated with anxiety or depressive symptoms, whereas the relation of hsCRP to Type D personality was unexplored, and the impact of hsCRP on HRQoL was undetermined in AF patients.
Aim:
To determine whether Type D personality and hsCRP are independently associated with impaired HRQoL.
Methods:
A cross-sectional study design was used among a total of 114 patients with chronic AF. Patients underwent measurements of serum levels of hsCRP. Type D personality, anxiety and depressive symptoms, and HRQoL were assessed by the Type D Scale, the Hospital Anxiety and Depression Scale, and the Short-Form Medical Outcomes Survey, respectively. Hierarchical linear regression was used to determine the impact of Type D personality and hsCRP on HRQoL.
Results:
Thirty-two percent of patients had Type D personality. Patients with Type D personality had higher hsCRP than those with non-Type D personality (1.4 ± 1.9 vs. 0.6 ± 2.2, p = 0.046). In hierarchical linear regression, Type D personality (β = − 0.28; p = 0.005) and hsCRP (β = − 0.21; p = 0.034) were independently associated with HRQoL controlling for clinical risk factors, anxiety, and depression symptoms.
Conclusions:
Type D personality and hsCRP are independent predictors of impaired HRQoL. Clinicians need to pay attention to patients with Type D personality and monitor serum levels of hsCRP to prevent impaired HRQoL in AF patient.
GoASHylekEMPhillipsKAChangYHenaultLESelbyJV. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMAMay92001; 285(18): 2370–2375.
2.
FrestoneBLipG.Y.H. Epidemiology and costs of cardiac arrhythmias. LipG.Y.HGodtfredsenJ. Cardiac arrhythmias: aclinical approach. Edinburgh: Mosby; 2003. 3–24.
3.
DorianPJungWNewmanDPaquetteMWoodKAyersGM. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll CardiolOct 2000; 36(4): 1303–1309.
4.
van den BergMPHassinkRJTuinenburgAEvan SonderenEFLefrandtJDde KamPJ. Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system. Eur Heart JFeb 2001; 22(3): 247–253.
5.
ThrallGLaneDCarrollDLipGY. Quality of life in patients with atrial fibrillation: a systematic review. Am J MedMay2006; 119(5): 448e1–19.
6.
LonnerholmSBlomstromPNilssonLOxelbarkSJideusLBlomstrom-LundqvistC. Effects of the maze operation on health-related quality of life in patients with atrial fibrillation. CirculationJun62000; 101(22): 2607–2611.
7.
LaneDALangmanCMLipGYNouwenA. Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation. J Psychosom ResMar2009; 66(3): 203–210.
8.
KrumholzHMPetersonEDAyanianJZChinMHDeBuskRFGoldmanL. Report of the National Heart, Lung, and Blood Institute working group on outcomes research in cardiovascular disease. CirculationJun142005; 111(23): 3158–3166.
9.
NewmanD. Quality of life as an endpoint for atrial fibrillation research: pitfalls and practice. Heart RhythmJul2004; 1(2 Suppl.): B20-B25discussion B5–6..
10.
DorianPMangatI. Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation. Card Electrophysiol RevSep2003; 7(3): 276–279.
11.
SavelievaIPaquetteMDorianPLuderitzBCammAJ. Quality of life in patients with silent atrial fibrillation. HeartFeb2001; 85(2): 216–217.
12.
ReynoldsMRLavelleTEssebagVCohenDJZimetbaumP. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart JDec2006; 152(6): 1097–1103.
13.
ThrallGLipGYCarrollDLaneD. Depression, anxiety, and quality of life in patients with atrial fibrillation. ChestOct2007; 132(4): 1259–1264.
14.
LangeHWHerrmann-LingenC. Depressive symptoms predict recurrence of atrial fibrillation after cardioversion. J Psychosom ResNov2007; 63(5): 509–513.
15.
OngLCribbieRHarrisLDorianPNewmanDMangatI. Psychological correlates of quality of life in atrial fibrillation. Qual Life ResOct2006; 15(8): 1323–1333.
16.
DenolletJ. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom MedJan-Feb 2005; 67(1): 89–97.
17.
PedersenSSHerrmann-LingenCde JongePSchererM. Type D personality is a predictor of poor emotional quality of life in primary care heart failure patients independent of depressive symptoms and New York Heart Association functional class. J Behav MedNov242009.
18.
YuDSThompsonDRYuCMPedersenSSDenolletJ. Validating the Type D personality construct in Chinese patients with coronary heart disease. J Psychosom ResAug2010; 69(2): 111–118.
19.
AquariusAEDenolletJde VriesJHammingJF. Poor health-related quality of life in patients with peripheral arterial disease: type D personality and severity of peripheral arterial disease as independent predictors. J Vasc SurgSep2007; 46(3): 507–512.
20.
AquariusAEDenolletJHammingJFDe VriesJ. Role of disease status and type D personality in outcomes in patients with peripheral arterial disease. Am J CardiolOct12005; 96(7): 996–1001.
21.
PedersenSSHolkampPGCaliskanKvan DomburgRTErdmanRABalkAH. Type D personality is associated with impaired health-related quality of life 7 years following heart transplantation. J Psychosom ResDec2006; 61(6): 791–795.
22.
ChungMKMartinDOSprecherDWazniOKanderianACarnesCA. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. CirculationDec112001; 104(24): 2886–2891.
23.
DernellisJPanaretouM. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta CardiolDec2001; 56(6): 375–380.
24.
AvilesRJMartinDOApperson-HansenCHoughtalingPLRautaharjuPKronmalRA. Inflammation as a risk factor for atrial fibrillation. CirculationDec162003; 108(24): 3006–3010.
25.
GedikliODoganAAltuntasIAltinbasAOzaydinMAkturkO. Inflammatory markers according to types of atrial fibrillation. Int J CardiolAug212007; 120(2): 193–197.
26.
MaloufJFKanagalaRAl AtawiFORosalesAGDavisonDEMuraliNS. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll CardiolOct.42005; 46(7): 1284–1287.
27.
HowrenMBLamkinDMSulsJ. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom MedFeb2009; 71(2): 171–186.
28.
BankierBBarajasJMartinez-RumayorAJanuzziJL. Association between anxiety and C-reactive protein levels in stable coronary heart disease patients. PsychosomaticsJul-Aug2009; 50(4): 347–353.
29.
BankierBBarajasJMartinez-RumayorAJanuzziJL. Association between major depressive disorder and C-reactive protein levels in stable coronary heart disease patients. J Psychosom ResMar2009; 66(3): 189–194.
30.
Frasure-SmithNLesperanceFIrwinMRTalajicMPollockBG. The relationships among heart rate variability, inflammatory markers and depression in coronary heart disease patients. Brain Behav ImmunNov2009; 23(8): 1140–1147.
31.
ErdfelderEFaulFBuchnerA. GPOWER: a general power analysis program. Behav Res Methods Instrum Comput1996; 28:1–11.
32.
FaulFErdfelderELangAGBuchnerA. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res MethodsMay2007; 39(2): 175–191.
33.
FusterVRydenLECannomDSCrijnsHJCurtisABEllenbogenKA. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. CirculationAug152006; 114(7): e257–e354.
34.
StewartALHaysRDWareJE. The MOS short-form general health survey. Reliability and validity in a patient population. Med CareJul1988; 26(7): 724–735.
LogeJHKaasaS. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc MedDec1998; 26(4): 250–258.
37.
HanCWLeeEJIwayaTKataokaHKohzukiM. Development of the Korean version of Short-Form 36-Item Health Survey: health related QOL of healthy elderly people and elderly patients in Korea. Tohoku J Exp MedJul2004; 203(3): 189–194.
38.
KohSChanSKangGChaBParkJ. Reliability and validity on measurement instrument for health status assessment in occupational workers. J Prev Med Public Health1997; 30(2): 251–266.
39.
EmonsWHMeijerRRDenolletJ. Negative affectivity and social inhibition in cardiovascular disease: evaluating type-D personality and its assessment using item response theory. J Psychosom ResJul2007; 63(1): 27–39.
40.
LimHELeeMSKoYHParkYMJoeSHKimYK. Assessment of the type D personality construct in the Korean population: avalidation study of the Korean DS14. J Korean Med SciJan2011; 26(1): 116–123.
41.
HerrmannC. International experiences with the Hospital Anxiety and Depression Scale—a review of validation data and clinical results. J Psychosom ResJan1997; 42(1): 17–41.
42.
ZigmondASSnaithRP. The hospital anxiety and depression scale. Acta Psychiatr ScandJun1983; 67(6): 361–370.
43.
BjellandIDahlAAHaugTTNeckelmannD. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res2002 Feb; 52(2): 69–77.
44.
BroekhuizenRWoutersEFCreutzbergECScholsAM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. ThoraxJan2006; 61(1): 17–22.
45.
RibuLRustoenTBirkelandKHanestadBRPaulSMMiaskowskiC. The prevalence and occurrence of diabetic foot ulcer pain and its impact on health-related quality of life. J PainApr2006; 7(4): 290–299.
46.
RidkerPMRifaiNRoseLBuringJECookNR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J MedNov142002; 347(20): 1557–1565.
47.
RidkerPM. C-reactive protein: a simple test to help predict risk of heart attack and stroke. CirculationSep232003; 108(12): e81-5Cardiology Patient Page.
48.
HongYJJeongMHParkOYKimWKimJHAhnYK. The role of C-reactive protein on the long-term clinical outcome after primary or rescue percutaneous coronary intervention. Korean J Intern MedMar2003; 18(1): 29–34.
49.
PearsonTAMensahGAAlexanderRWAndersonJLCannonROCriquiM. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. CirculationJan282003; 107(3): 499–511.
50.
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. LancetJan102004; 363(9403): 157–163.
51.
SongEKSonYJ. The analysis of type D personality research as a psychosocial risk factor in cardiovascular disease for elders with a chronic disease. Taehan Kanho Hakhoe ChiFeb2008; 38(1): 19–28.
52.
PedersenSSDenolletJ. Is Type D personality here to stay? Emerging evidence across cardiovascular disease patient groups. Curr Cardiol Rev2006; 2205–213.
53.
MolsFDenolletJ. Type D personality among noncardiovascular patient populations: a systematic review. Gen Hosp PsychiatryJan-Feb2010; 32(1): 66–72.
54.
SteptoeAMolloyGJ. Personality and heart disease. HeartJul2007; 93(7): 783–784.
55.
PelleAJSchifferAASmithORWiddershovenJWDenolletJ. Inadequate consultation behavior modulates the relationship between Type D personality and impaired health status in chronic heart failure. Int J CardiolJan222009.
56.
SchifferAADenolletJWiddershovenJWHendriksEHSmithOR. Failure to consult for symptoms of heart failure in patients with a type-D personality. HeartJul2007; 93(7): 814–818.
57.
WilliamsLO’ConnorRCHowardSHughesBMJohnstonDWHayJL. Type-D personality mechanisms of effect: the role of health-related behavior and social support. J Psychosom ResJan2008; 64(1): 63–69.
58.
EinvikGDammenTHrubos-StrømHNamtvedtSKRandbyAKristiansenHA. Prevalence of cardiovascular risk factors and concentration of C-reactive protein in Type D personality persons without cardiovascular disease. Eur J Cardiovasc Prev Rehabil2011; 1–6.
59.
ConraadsVMDenolletJDe ClerckLSStevensWJBridtsCVrintsCJ. Type D personality is associated with increased levels of tumour necrosis factor (TNF)-alpha and TNF-alpha receptors in chronic heart failure. Int J CardiolOct262006; 113(1): 34–38.
60.
DenolletJConraadsVMBrutsaertDLDe ClerckLSStevensWJVrintsCJ. Cytokines and immune activation in systolic heart failure: the role of Type D personality. Brain Behav ImmunAug2003; 17(4): 304–309.
61.
DenolletJSchifferAAKwaijtaalMHooijkaasHHendriksEHWiddershovenJW. Usefulness of Type D personality and kidney dysfunction as predictors of interpatient variability in inflammatory activation in chronic heart failure. Am J CardiolFeb12009; 103(3): 399–404.
62.
DenolletJVrintsCJConraadsVM. Comparing Type D personality and older age as correlates of tumor necrosis factor-alpha dysregulation in chronic heart failure. Brain Behav ImmunJul2008; 22(5): 736–743.
63.
HabraMELindenWAndersonJCWeinbergJ. Type D personality is related to cardiovascular and neuroendocrine reactivity to acute stress. J Psychosom ResSep2003; 55(3): 235–245.
64.
CarpeggianiCEmdinMBonaguidiFLandiPMichelassiCTrivellaMG. Personality traits and heart rate variability predict long-term cardiac mortality after myocardial infarction. Eur Heart JAug2005; 26(16): 1612–1617.
65.
IssacTTDokainishHLakkisNM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll CardiolNov202007; 50(21): 2021–2028.
